Table 3.
Patient and tumour characteristics of pT1a-pT1b tumours vs other stage I-II tumours in the NEMESI study
| Pathological stage I-II (pT1a, pT1b excluded) | pT1a, pT1b | |
|---|---|---|
|
N. of patients |
1492 |
402 |
|
Distribution by age |
|
|
| 18–34 |
23 (1.5%) |
7 (1.7%) |
| 35–49 |
384 (25.7%) |
85 (21.1%) |
| 50–69 |
754 (50.5%) |
230 (57.2%) |
| ≥ 70 |
331 (22.2%) |
80 (19.9%) |
|
Menopausal status |
|
|
| Pre- |
465 (31.2%) |
101 (25.1%) |
| Post- |
1,014 (68.0%) |
293 (72.8%) |
| Unknown |
13 (0.9%) |
8 (2.0%) |
|
Node sentinel biopsy |
|
|
| Yes |
903 (60.5%) |
319 (79.3%) |
| No |
589 (39.5%) |
83 (20.7%) |
|
Axillary nodal dissection |
|
|
| Yes |
941 (63.1%) |
137 (34.1%) |
| No |
551 (36.9%) |
265 (65.9%) |
|
Grading |
|
|
| G1 |
120 (8.0%) |
101 (25.1%) |
| G2 |
741 (48.7%) |
221 (55.0%) |
| G3 |
589 (39.5%) |
72 (17.9%) |
| Unknown |
42 (2.8%) |
8 (2.0%) |
|
Proliferation index (Ki-67/MB1) |
|
|
| 0–18% |
707 (47.4%) |
283 (70.6%) |
| 19–29% |
279 (18.7%) |
52 (12.9%) |
| ≥ 30% |
461 (30.9%) |
54 (13.4%) |
| Unknown |
45 (3.0%) |
13 (3.2%) |
|
ER status |
|
|
| ER positive (≥ 10%) |
1,215 (81.4%) |
351 (87.3%) |
| ER negative (0–9%) |
276 (18.5%) |
51 (12.7%) |
| Unknown |
1 (0.1%) |
0 (0.0%) |
|
PgR status |
|
|
| PgR positive (≥ 10%) |
1,038 (69.6%) |
300 (74.6%) |
| PgR negative (0–9%) |
449 (30.1%) |
101 (25.4%) |
| Unknown |
5 (0.3%) |
0 (0.0%) |
|
Hormonal status* |
|
|
| ER and/or PgR positive |
1,228 (82.3%) |
354 (88.1%) |
| ER and PgR negative |
263 (17.6%) |
48 (11.9%) |
| Unknown |
1 (0.1%) |
0 (0.0%) |
|
HER2 status** |
|
|
| Positive |
279 (18.7%) |
49 (12.2%) |
| Negative |
1,185 (79.4%) |
344 (85.6%) |
| Missing |
28 (1.9%) |
9 (2.2%) |
|
pN status |
|
|
| pN0 |
836 (56.0%) |
319 (79.4%) |
| pN1 (1–3) |
477 (32.0%) |
74 (18.4%) |
| pN2 (4–9) |
113 (7.6%) |
6 (1.5%) |
| pN3 (≥ 10) | 66 (4.4%) | 3 (0.7%) |
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH